Results 231 to 240 of about 163,614 (303)

Zuranolone: A case study in (regulatory) rush to judgement?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove   +4 more
wiley   +1 more source

Brain-wide properties of slow waves across vigilance states. [PDF]

open access: yesSleep Adv
Yang S, Poole O, Walker MC, Sheybani L.
europepmc   +1 more source

Safety concerns reported by coroners following fentanyl patch fatalities in England, Wales and Northern Ireland between 1997 and 2024

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim To identify safety concerns reported by coroners following fentanyl patch‐related deaths in England, Wales and Northern Ireland, and determine differences in coronial reporting. Methods A systematic case series linking the National Programme on Substance Use Mortality (NPSUM) and the Preventable Deaths Tracker (PDT) (https ...
Eman Mshari   +2 more
wiley   +1 more source

Acute toxicity of ADB‐CHMINACA ‐ a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndrome

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim This report presents a series of 16 patients who were admitted to the emergency department following confirmed intake of the potent synthetic cannabinoid ADB‐CHMINACA. Methods The cases are drawn from a prospective observational study following the recreational use of synthetic cannabinoids.
Maren Hermanns‐Clausen   +7 more
wiley   +1 more source

Awareness of the Black Triangle Scheme among healthcare professionals and consumers in Australia: A mixed‐methods study exploring reporting intentions and suggested improvements

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims The Black Triangle Scheme, introduced in 2018 in Australia, does not appear to have increased the quantity of adverse drug event (ADE) reports. This study evaluated healthcare professionals' (HCPs') and consumers' awareness of the scheme, its influence on intentions for future ADE reporting, and suggested improvements.
Eyob Alemayehu Gebreyohannes   +7 more
wiley   +1 more source

Potential for use of Al/machine learning for pharmacovigilance: Is there a role for regulators?

open access: yes
British Journal of Clinical Pharmacology, EarlyView.
Christina Gao   +3 more
wiley   +1 more source

Glucocorticoid exposure and initiation of SSRIs among patients with rheumatoid arthritis: A nested case–control study in UK primary care

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim The immune system might affect the development of anxiety disorders, though mechanisms remain unclear. This nested case–control study investigates whether use of glucocorticoids, potent immunosuppressants, is associated with SSRI initiation (a proxy for pharmacologically treated mental disorders, predominantly depression and/or anxiety).
Elise J. Heesbeen   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy